Enacted — Signed by the President — Jul 9, 2012
Last Action: Signed by President.
Explanation: This bill was enacted after being signed by the President on July 9, 2012.
Mar 26, 2012
112th Congress, 2011–2013
This bill was introduced on March 26, 2012, in a previous session of Congress, but was not enacted.
Senior Senator from Colorado
Read Text »
Last Updated: Mar 26, 2012
Length: 8 pages
A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.
Enacted — Signed by the President
Jul 9, 2012
Reported by Committee
Last Action: May 7, 2012
The “S.” in “S. 2236” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
Search for similar bills.
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s2236
“S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012.” www.GovTrack.us. 2012. September 4, 2015 <https://www.govtrack.us/congress/bills/112/s2236>
|title=S. 2236 (112th)
|accessdate=September 4, 2015
|author=112th Congress (2012)
|date=March 26, 2012
|quote=Advancing Breakthrough Therapies for Patients Act of 2012